High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents

A cell delivery strategy was investigated that was hypothesized to enable magnetic targeting of endothelial cells to the steel surfaces of intraarterial stents because of the following mechanisms: (i) preloading cells with biodegradable polymeric superparamagnetic nanoparticles (MNPs), thereby rendering the cells magnetically responsive; and (ii) the induction of both magnetic field gradients around the wires of a steel stent and magnetic moments within MNPs because of a uniform external magnetic field, thereby targeting MNP-laden cells to the stent wires. In vitro studies demonstrated that MNP-loaded bovine aortic endothelial cells (BAECs) could be magnetically targeted to steel stent wires. In vivo MNP-loaded BAECs transduced with adenoviruses expressing luciferase (Luc) were targeted to stents deployed in rat carotid arteries in the presence of a uniform magnetic field with significantly greater Luc expression, detected by in vivo optical imaging, than nonmagnetic controls.

[1]  Patrick W Serruys,et al.  Coronary-artery stents. , 2006, The New England journal of medicine.

[2]  Rossella Fattori,et al.  Drug-eluting stents in vascular intervention , 2003, The Lancet.

[3]  D. Collen,et al.  Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. , 1998, Circulation.

[4]  Sung‐Wook Choi,et al.  Design of surface-modified poly(D,L-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[5]  C. Alexiou,et al.  Locoregional cancer treatment with magnetic drug targeting. , 2000, Cancer research.

[6]  W. Erhardt,et al.  Magnetisches Drug Targeting—ein neuer Ansatz in der lokoregionären Tumortherapie mit Chemotherapeutika , 2005, HNO.

[7]  Jayanth Panyam,et al.  Dynamics of Endocytosis and Exocytosis of Poly(D,L-Lactide-co-Glycolide) Nanoparticles in Vascular Smooth Muscle Cells , 2003, Pharmaceutical Research.

[8]  R. Virmani,et al.  A Novel Rat Model of Carotid Artery Stenting for the Understanding of Restenosis in Metabolic Diseases , 2002, Journal of Vascular Research.

[9]  G. Stone,et al.  Update on drug-eluting coronary stents , 2005, Expert review of cardiovascular therapy.

[10]  Rajiv Gulati,et al.  Magnetically targeted endothelial cell localization in stented vessels. , 2006, Journal of the American College of Cardiology.

[11]  R. Vile,et al.  Autologous Culture-Modified Mononuclear Cells Confer Vascular Protection After Arterial Injury , 2003, Circulation.

[12]  M. Shive,et al.  Biodegradation and biocompatibility of PLA and PLGA microspheres , 1997 .

[13]  Scott Goodwin,et al.  Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers , 2003, Cancer Chemotherapy and Pharmacology.

[14]  D. Huhn,et al.  Preclinical experiences with magnetic drug targeting: tolerance and efficacy. , 1996, Cancer research.

[15]  I. Alferiev,et al.  Bisphosphonate-mediated gene vector delivery from the metal surfaces of stents. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Rajiv Gulati,et al.  Magnetic Forces Enable Rapid Endothelialization of Synthetic Vascular Grafts , 2006, Circulation.

[17]  Christoph Alexiou,et al.  Magnetic Drug Targeting—Biodistribution of the Magnetic Carrier and the Chemotherapeutic agent Mitoxantrone after Locoregional Cancer Treatment , 2003 .

[18]  D. Quintanar-Guerrero,et al.  Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. , 1998, Drug development and industrial pharmacy.

[19]  R Weissleder,et al.  Superparamagnetic iron oxide: pharmacokinetics and toxicity. , 1989, AJR. American journal of roentgenology.

[20]  S. Goodwin,et al.  Single-dose toxicity study of hepatic intra-arterial infusion of doxorubicin coupled to a novel magnetically targeted drug carrier. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[21]  A. Mangi,et al.  Enhanced Inhibition of Neointimal Hyperplasia by Genetically Engineered Endothelial Progenitor Cells , 2004, Circulation.

[22]  Gary Friedman,et al.  Magnetically driven plasmid DNA delivery with biodegradable polymeric nanoparticles , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  Jon Dobson,et al.  Improved method of recombinant AAV2 delivery for systemic targeted gene therapy. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  Robert J Levy,et al.  Adenoviral gene vector tethering to nanoparticle surfaces results in receptor-independent cell entry and increased transgene expression. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  E. Topol,et al.  Effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury. , 1995, Circulation research.

[26]  P M Consigny,et al.  Use of endothelial cells containing superparamagnetic microspheres to improve endothelial cell delivery to arterial surfaces after angioplasty. , 1999, Journal of vascular and interventional radiology : JVIR.

[27]  C Alexiou,et al.  [Magnetic Drug Targeting--a new approach in locoregional tumor therapy with chemotherapeutic agents. Experimental animal studies]. , 2005, HNO.

[28]  W. Hunter,et al.  Drug-eluting stents: a multidisciplinary success story. , 2006, Advanced drug delivery reviews.